Recursion Pharmaceuticals Inc
RXRX.O- Latest Trade
- trading higher8.85USD
- Change
- 0.42
- % Change
4.98%Positive
- Day Range
- 8.25 - 8.95
- 52-Week Range
- 4.92 - 42.81
As of Jul 5 2022. Values delayed up to 15 minutes
- Previous Close
- 8.43
- Open
- 8.25
- Volume
- 1,197,711.00
- 3 Month Average Trading Volume
- 22.45
- Shares Out (Mil)
- 172.01
- Market Cap
- 1,450.02
- Forward P/E
- -5.38
- Dividend Yield
- -99,999.99
Key Statistics
2.8 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 111.98
- Price To Book (Quarterly)
- 2.92
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.14
- Long Term Debt/Equity (Quarterly)
- 0.12
- Return On Investment (TTM)
- -47.39
- Return On Equity (TTM)
- -42.08
2021 (millions USD)
About Recursion Pharmaceuticals Inc
Company Information
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company decoding biology by integrating technology across biology, chemistry, automation, machine learning, and engineering to industrialize drug discovery. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.
Address
41S Rio Grande StreetSALT LAKE CITY, UT
84101
United States
Industry
Business Services
Executive Leadership
- R. Martin Chavez
- Independent Chairman of the Board
- Tina Marriott Larson
- President, Chief Operating Officer
- Christopher Gibson
- Chief Executive Officer, Director
- Michael Secora
- Chief Financial Officer
- Shafique Virani
- Chief Business Officer, Interim Chief Medical Officer
- Zachary Bogue
- Independent Director
- Blake Borgeson
- Independent Director
- Terry - Ann Burrell
- Independent Director
- Zavain Dar
- Independent Director
- Robert M. Hershberg
- Independent Director
- Dean Y. Li
- Independent Director
Latest News
- MarketsU.S. airlines, Recursion Pharma, Veritex
Wall Street's main indexes fell in a broad decline on Friday as the intensifying war in Ukraine overshadowed an acceleration in jobs growth last month that highlighted the strength of the U.S. economy.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,761.80 | -- |
| Copper | 651.25 | -- |
| Brent Crude Oil | 103.65 | 0.86%Positive |
| CBOT Soybeans | 1,572.00 | 0.21%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,831.39 | 0.16%Positive |
| Euro STOXX 50 | 3,359.83 | -- |
| FTSE 100 | 7,025.47 | 2.86%Negative |
| Nikkei 225 | 26,089.86 | 1.26%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes